DK0948614T3 - Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme - Google Patents

Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme

Info

Publication number
DK0948614T3
DK0948614T3 DK97954089T DK97954089T DK0948614T3 DK 0948614 T3 DK0948614 T3 DK 0948614T3 DK 97954089 T DK97954089 T DK 97954089T DK 97954089 T DK97954089 T DK 97954089T DK 0948614 T3 DK0948614 T3 DK 0948614T3
Authority
DK
Denmark
Prior art keywords
immunomodulation
treatment
malignancies
autoimmune diseases
expression vectors
Prior art date
Application number
DK97954089T
Other languages
Danish (da)
English (en)
Inventor
Mark Cantwell
Thomas J Kipps
Sanjai Sharma
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0948614T3 publication Critical patent/DK0948614T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK97954089T 1996-12-09 1997-12-08 Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme DK0948614T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3214596P 1996-12-09 1996-12-09
US08/982,272 US7070771B1 (en) 1996-12-09 1997-12-01 Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
PCT/US1997/022740 WO1998026061A2 (en) 1996-12-09 1997-12-08 Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease

Publications (1)

Publication Number Publication Date
DK0948614T3 true DK0948614T3 (da) 2009-05-11

Family

ID=26708033

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97954089T DK0948614T3 (da) 1996-12-09 1997-12-08 Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme

Country Status (16)

Country Link
US (3) US7070771B1 (es)
EP (4) EP0948614B1 (es)
JP (1) JP4015201B2 (es)
CN (1) CN1221662C (es)
AT (2) ATE547524T1 (es)
AU (1) AU5795798A (es)
BR (1) BR9714004A (es)
CA (2) CA2274498C (es)
DE (1) DE69739220D1 (es)
DK (1) DK0948614T3 (es)
ES (1) ES2321246T3 (es)
IL (3) IL130247A0 (es)
NO (2) NO327411B1 (es)
NZ (1) NZ336092A (es)
PT (1) PT948614E (es)
WO (1) WO1998026061A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
AU3966200A (en) * 1999-04-16 2000-11-02 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
GB9917180D0 (en) * 1999-07-23 1999-09-22 Univ Sheffield Cell surface receptor
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
AU2003207349A1 (en) * 2002-02-25 2003-09-09 Isis Innovation Limted Novel complexes for inducing an immune response
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20080044393A1 (en) * 2004-07-16 2008-02-21 White Robert L Retinal dystrophin transgene and methods of use thereof
WO2008109825A2 (en) * 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
NZ707336A (en) * 2012-10-17 2019-01-25 Vascular Biogenics Ltd Treatment methods using adenovirus
CN106574241A (zh) * 2014-03-27 2017-04-19 密执安大学评议会 癌症免疫疗法组合物和方法
SG11201609118RA (en) 2014-05-15 2016-11-29 Univ Singapore Modified natural killer cells and uses thereof
CN105567679B (zh) * 2014-10-10 2019-07-05 深圳市北科生物科技有限公司 可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS
MX2021010670A (es) 2019-03-05 2021-11-12 Nkarta Inc Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
CN112725379A (zh) * 2021-01-27 2021-04-30 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
US11585330B1 (en) * 2021-09-29 2023-02-21 Halliburton Energy Services, Inc. Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US5095096A (en) 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
JP2930713B2 (ja) 1989-08-16 1999-08-03 カイロン コーポレイション タンパク質ホルモン形成の抑制用の組成物およびその使用法
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
EP0897983B1 (en) 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
WO1993019777A1 (en) 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
SK376492A3 (en) 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
ES2211876T3 (es) 1993-01-22 2004-07-16 Immunex Corporation Deteccion y tratamiento de mutaciones en un gel del ligando de cd40.
JP4242447B2 (ja) 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
NZ278740A (en) 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
NZ279108A (en) 1994-01-07 1997-06-24 Immunex Corp Human fas (tgf/ngf receptor) ligand proteins coding sequences and production
CA2188165C (en) 1994-04-28 2007-08-28 Marilyn Kehry Methods for proliferating and differentiating b cells, and uses thereof
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
AU3111995A (en) 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) * 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
ATE460482T1 (de) 1997-09-17 2010-03-15 Mochida Pharm Co Ltd Fas-liganden derivate
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
WO1998026061A3 (en) 1998-11-19
PT948614E (pt) 2009-04-20
CA2274498A1 (en) 1998-06-18
US20100267129A1 (en) 2010-10-21
US7906638B2 (en) 2011-03-15
CN1221662C (zh) 2005-10-05
EP2145958A1 (en) 2010-01-20
EP0948614A2 (en) 1999-10-13
JP4015201B2 (ja) 2007-11-28
ATE547524T1 (de) 2012-03-15
ES2321246T3 (es) 2009-06-03
EP1806360A3 (en) 2007-12-12
CN1246892A (zh) 2000-03-08
CA2707726A1 (en) 1998-06-18
CA2707726C (en) 2013-10-22
NO992756L (no) 1999-08-09
US7524944B2 (en) 2009-04-28
NO20074906L (no) 1999-08-09
NO992756D0 (no) 1999-06-07
BR9714004A (pt) 2000-05-02
US20060183199A1 (en) 2006-08-17
NZ336092A (en) 2001-09-28
IL130247A (en) 2008-03-20
NO327411B1 (no) 2009-06-22
EP2145958B1 (en) 2012-02-29
EP1806360A2 (en) 2007-07-11
IL178306A0 (en) 2007-02-11
NO331434B1 (no) 2011-12-27
EP0948614B1 (en) 2009-01-14
US7070771B1 (en) 2006-07-04
EP2287309A1 (en) 2011-02-23
JP2001505782A (ja) 2001-05-08
IL130247A0 (en) 2000-06-01
CA2274498C (en) 2010-06-29
WO1998026061A2 (en) 1998-06-18
AU5795798A (en) 1998-07-03
DE69739220D1 (de) 2009-03-05
ATE420956T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
DK0948614T3 (da) Nye ekspressionsvektorer indeholdende accessoriske molekylligandgener og deres anvendelse til immunmodulation og behandling af maligniteter og autoimmunsygdomme
PT662137E (pt) Transcricao de genes e radiacao ionizante: metodos e composicoes
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
IL190793A0 (en) A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
ATE437232T1 (de) Rekombinanter adenoviren-vektor und verfahren zur verwendung
DE3587939T2 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.
ATE208425T1 (de) Kodierende sequenzen des menschlichen brca1-gens
DE69940964D1 (de) Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
ATE481986T1 (de) Polynukleotidkonstrukte, pharmazeutische zusammensetzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
DK1390403T3 (da) Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf
DK1368054T3 (da) Anvendelse af neurale trådproteiner til behandling af tumorer
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
EP1100815A4 (en) PROTEASE TYPE II CLEAVABLE PEPTIDE
ATE517122T1 (de) Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
FI20050753A (fi) Uudet peptidit
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
DK1255829T3 (da) Inhibitor af hepatocytvækstfaktoraktivator til anvendelse i modulation af angiogenese og kardiovaskularisering
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE291738T1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
ATE290394T1 (de) Verwendung von adenoassoziierten viren zur senkung der radio- oder chemotherapieinduzierten resistenz bei krebspatienten